Division of Infectious Disease, Department of Pediatrics, Medical School of Ege University, Izmir, Turkey.
Department of Medical Microbiology, Ege University Faculty of Medicine, İzmir, Turkey.
Hum Vaccin Immunother. 2021 Nov 2;17(11):4190-4193. doi: 10.1080/21645515.2021.1967037. Epub 2021 Oct 13.
Varicella is a vaccine-preventable disease, and the incidence of varicella has declined since the introduction of varicella vaccine campaigns. A wild type of varicella zoster virus (VZV) was isolated from a 33-month-old child with varicella in Korea in 1989, a different strain (MAV/06). A live-attenuated varicella vaccine containing strain (MAV/06), Suduvax®, was developed in South Korea in 1994. Turkey introduced the varicella vaccine containing the MAV/06 strain (Varicella Vaccine-GCC, Green Cross, South Korea) in January 2019. Therefore, we aimed to compare the seroconversion rates among MAV/06 vaccine- and vOka-administered children. We prospectively collected blood samples from 98 received vOKA and 98 received MAV/06 children 6 weeks after administration, and seroconversion rates were determined by an indirect fluorescence assay (Anti-VZV IIFT IgG, Euroimmun, Germany). Seroconversion rate was significantly higher in vOka group than MAV/06 group (82.7% vs. 64.3%; ). Of the children vaccinated with vOka strain, 17 children did not develop antibodies, 12 were weakly positive, and the remaining 69 children were strongly positive. Of the children who were administered MAV/06 strain, 35 were negative, 20 were weakly positive, and 43 were strongly positive. In conclusion, this study demonstrated that MAV/06 varicella vaccine had lower seroconversion rates and the strong seropositive cases were less common than vOka-administered children. Larger and prospective studies are needed.
水痘是一种可通过疫苗预防的疾病，自从开展水痘疫苗接种活动以来，水痘的发病率有所下降。1989 年，韩国从一名 33 月龄患水痘的儿童中分离出一株野生型水痘带状疱疹病毒（VZV），为不同株（MAV/06）。韩国于 1994 年开发了一种含有 MAV/06 株（MAV/06）的减毒活水痘疫苗（Suduvax®）。土耳其于 2019 年 1 月引入了含有 MAV/06 株的水痘疫苗（Varicella Vaccine-GCC，Green Cross，韩国）。因此，我们旨在比较 MAV/06 疫苗和 vOka 接种儿童的血清转化率。我们前瞻性地收集了 98 名接受 vOKA 和 98 名接受 MAV/06 儿童在接种后 6 周的血液样本，并通过间接荧光测定法（Anti-VZV IIFT IgG，Euroimmun，德国）确定血清转化率。vOka 组的血清转化率明显高于 MAV/06 组（82.7% vs. 64.3%）。接种 vOka 株的儿童中，有 17 名儿童未产生抗体，12 名儿童抗体弱阳性，其余 69 名儿童抗体强阳性。接种 MAV/06 株的儿童中，有 35 名儿童抗体阴性，20 名儿童抗体弱阳性，43 名儿童抗体强阳性。总之，本研究表明，MAV/06 水痘疫苗的血清转化率较低，且强阳性病例比接种 vOka 疫苗的儿童少见。需要进行更大规模和前瞻性的研究。
